Ryan Lewis Smith, a director and 10% owner of 180 Life Sciences Corp, has filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated March 7, 2024, indicates that Smith does not beneficially own any non-derivative or derivative securities of the company. The form, signed on March 11, 2024, is a standard disclosure for insiders of public companies, detailing their holdings and transactions in the company's stock. This filing is part of the regulatory compliance under Section 16(a) of the Securities Exchange Act of 1934.

Ryan Lewis Smith, a director and 10% owner of 180 Life Sciences Corp, has filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated March 7, 2024, indicates that Smith does not beneficially own any non-derivative or derivative securities of the company. The form, signed on March 11, 2024, is a standard disclosure for insiders of public companies, detailing their holdings and transactions in the company's stock. This filing is part of the regulatory compliance under Section 16(a) of the Securities Exchange Act of 1934.